Akari Therapeutics Reports Preclinical Success of Novel ADC in KRAS-Mutant Pancreatic Cancer

Akari Therapeutics Plc Sponsored ADR

AKTX

0.00

Akari Therapeutics plc has announced new preclinical data demonstrating the therapeutic potential of its lead antibody drug conjugate (ADC), AKTX-101, in treating hard-to-treat KRAS-mutant pancreatic cancer. The research highlights that AKTX-101, which targets the Trop2 receptor and delivers a novel spliceosome modulating payload (PH1), showed significant activity and prolonged survival in preclinical animal models compared to traditional ADCs. The results also suggest potential synergy with checkpoint inhibitors. Akari plans to advance AKTX-101 into clinical testing by late 2026 or early 2027. The newly announced data were discussed by the company’s CEO in a recent Virtual Investor "What This Means" segment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9603996-en) on December 18, 2025, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.